Investor Relations

Consolidated Earnings Briefing

Kaken Pharmaceutical Co., Ltd. and Consolidated Subsidiaries

2017 2016
For the years ended March 31, Millions of yen
Net sales ¥101,479 ¥109,730
Operating income 30,707 35,146
Net income 22,017 21,143
At March 31,
Total net assets 102,655 89,875
Total assets 135,060 132,991
Per share data: Yen
Net income (Basic) ¥536.70 ¥510.54
* The Company conducted a reverse stock split to consolidate every two shares of common stock into one share on October 1, 2015. Basic earnings per share has been calculated assuming that the reverse stock split was conducted at the beginning of the previous consolidated fiscal year.
Cash dividends
End of second quarter 75.00 34.00
Year-end 75.00 78.00
Total 150.00 -
* The Company conducted a reverse stock split to consolidate every two shares of common stock into one share on October 1, 2015. The amount from before the reverse stock split is listed in the end of the second quarter, the year-end cash dividends per share for fiscal 2015 is the amount that factors in this reverse stock split, and total annual cash dividends are described as “-.”
ROE (%) 22.9 25.3
Capital adequacy ratio (%) 76.0 67.6

Forecasts

May 10, 2017

Forecasts of consolidated results for the Fiscal 2017
(April 1, 2017 - March 31, 2018 )

Full year
Millions of yen
Sales ¥101,700
Operating income 26,800
Net income 19,100

The above forecasts are based on the information available as of the date of the announcement of this data and assumptions made on the same day regarding various uncertainties that may affect our business results in the future. Actual business results may be greatly affected by various factors.